C4 Therapeutics Net Income Over Time
| CCCC Stock | USD 1.82 0.11 6.43% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out C4 Therapeutics Performance and C4 Therapeutics Correlation. Will Biotechnology sector continue expanding? Could CCCC diversify its offerings? Factors like these will boost the valuation of C4 Therapeutics. Projected growth potential of CCCC fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every C4 Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.57) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding C4 Therapeutics requires distinguishing between market price and book value, where the latter reflects CCCC's accounting equity. The concept of intrinsic value - what C4 Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push C4 Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between C4 Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding C4 Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, C4 Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare C4 Therapeutics and related stocks such as Insight Molecular, Sangamo Therapeutics, and Cybin Inc Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMDX | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (5 M) | (8.7 M) | (11.2 M) | (19.4 M) | (15.8 M) | (22.3 M) | (29.9 M) | (64.1 M) | (72.9 M) | (27.8 M) | (60.7 M) | (54.6 M) | (51.9 M) |
| SGMO | (308 K) | (35.8 M) | (22.3 M) | (26.6 M) | (26.4 M) | (40.7 M) | (71.7 M) | (54.6 M) | (68.3 M) | (75.8 M) | (121.1 M) | (178.3 M) | (192.3 M) | (257.8 M) | (97.9 M) | (88.1 M) | (83.7 M) |
| MOLN | 7.1 M | 7.1 M | 7.1 M | 7.1 M | (2.3 M) | (148.8 K) | (18.6 M) | (25.4 M) | (37 M) | (36.3 M) | (62.8 M) | (63.8 M) | 117.9 M | (62 M) | (54 M) | (48.6 M) | (46.2 M) |
| CDXS | (18.7 M) | (16.6 M) | (30.9 M) | (41.3 M) | (19.1 M) | (7.6 M) | (8.6 M) | (23 M) | (10.9 M) | (11.9 M) | (24 M) | (21.3 M) | (33.6 M) | (76.2 M) | (65.3 M) | (58.7 M) | (55.8 M) |
| PEPG | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.9 M) | (27.3 M) | (69.1 M) | (78.6 M) | (90 M) | (81 M) | (76.9 M) |
| ARMP | (5.1 M) | (3.8 M) | (1.1 M) | (64.6 M) | 23.1 M | (516 K) | (18.8 M) | (12.8 M) | (12.1 M) | (19.5 M) | (22.2 M) | (23.2 M) | (36.9 M) | (69 M) | (18.9 M) | (17 M) | (17.9 M) |
| SAVA | (4.5 M) | (2.6 M) | (3.4 M) | 31.5 M | (12.4 M) | (14.1 M) | (14.8 M) | (11.9 M) | (6.6 M) | (4.2 M) | (6.3 M) | (31.8 M) | (72.5 M) | (97.2 M) | (24.3 M) | (21.9 M) | (23 M) |
| OABI | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (17.6 M) | (27 M) | (22.3 M) | (50.6 M) | (62 M) | (55.8 M) | (53 M) |
| MIST | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (8.1 M) | (23.2 M) | (55.2 M) | (50 M) | (42.9 M) | (57.1 M) | (59.7 M) | (41.5 M) | (37.4 M) | (39.2 M) |
C4 Therapeutics and related stocks such as Insight Molecular, Sangamo Therapeutics, and Cybin Inc Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in C4 Therapeutics financial statement analysis. It represents the amount of money remaining after all of C4 Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| C4 Therapeutics | CCCC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 490 Arsenal Way, |
| Exchange | NASDAQ Exchange |
USD 1.82
Check out C4 Therapeutics Performance and C4 Therapeutics Correlation. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
C4 Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.